Nature reviews. Drug discovery

Sixty years of developing tiny fat particles to deliver genetic material

Updated

Abstract

Lipid nanoparticles (LNPs) have enabled the successful delivery of nucleic acid-based vaccines and therapeutics, exemplified by the COVID-19 mRNA vaccines and Onpattro.

  • Advances in lipid-based systems have addressed the challenge of delivering genetic information to target cells in vivo.
  • Clinically approved examples of LNPs include mRNA vaccines for COVID-19 and the small interfering RNA therapeutic Onpattro for amyloidosis.
  • Ongoing clinical development includes various promising LNP-enabled vaccines and gene therapies.
  • The success of LNPs is linked to research on lipoplexes with positively charged lipids and the use of ionizable cationic lipids in LNP design.
  • Insights from these research streams may provide delivery solutions for a wide range of gene therapies.

Simplified

Full Text

Full text is available at the source.

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free